141.35
price down icon0.72%   -1.02
after-market Handel nachbörslich: 141.60 0.25 +0.18%
loading
Schlusskurs vom Vortag:
$142.37
Offen:
$141.84
24-Stunden-Volumen:
1.11M
Relative Volume:
0.78
Marktkapitalisierung:
$20.60B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.62B
KGV:
12.77
EPS:
11.07
Netto-Cashflow:
$1.77B
1W Leistung:
-1.79%
1M Leistung:
-7.70%
6M Leistung:
-29.25%
1J Leistung:
-41.24%
1-Tages-Spanne:
Value
$140.75
$143.69
1-Wochen-Bereich:
Value
$140.75
$147.00
52-Wochen-Spanne:
Value
$139.71
$244.95

Biogen Inc Stock (BIIB) Company Profile

Name
Firmenname
Biogen Inc
Name
Telefon
(781) 464-2000
Name
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
7,570
Name
Twitter
@biogen
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
BIIB's Discussions on Twitter

Vergleichen Sie BIIB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BIIB
Biogen Inc
141.35 20.60B 9.61B 1.62B 1.77B 11.07
Drug Manufacturers - General icon
LLY
Lilly Eli Co
878.31 834.75B 45.04B 10.59B -2.28B 11.71
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
86.42 383.62B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.12 344.63B 88.82B 14.07B 19.03B 5.79
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.60 338.37B 56.33B 4.28B 15.62B 2.40
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.28 251.88B 64.17B 17.12B 14.84B 6.7297

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-02 Herabstufung Piper Sandler Overweight → Neutral
2024-12-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-12-16 Herabstufung Stifel Buy → Hold
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-09 Herabstufung Jefferies Buy → Hold
2024-11-18 Herabstufung Needham Buy → Hold
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-14 Eingeleitet Citigroup Neutral
2024-10-31 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-10-10 Fortgesetzt Raymond James Mkt Perform
2024-02-14 Bestätigt Needham Buy
2024-02-14 Herabstufung Wells Fargo Overweight → Equal Weight
2024-01-24 Herabstufung UBS Buy → Neutral
2023-12-20 Fortgesetzt Cantor Fitzgerald Overweight
2023-12-07 Hochstufung Raymond James Mkt Perform → Outperform
2023-09-06 Eingeleitet HSBC Securities Buy
2023-07-27 Eingeleitet Scotiabank Sector Outperform
2023-07-24 Bestätigt UBS Buy
2023-05-01 Hochstufung Guggenheim Neutral → Buy
2023-04-17 Hochstufung Piper Sandler Neutral → Overweight
2022-10-26 Hochstufung Goldman Neutral → Buy
2022-10-13 Hochstufung Stifel Hold → Buy
2022-10-07 Hochstufung Argus Hold → Buy
2022-09-28 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-09-28 Hochstufung Mizuho Neutral → Buy
2022-09-28 Hochstufung Robert W. Baird Neutral → Outperform
2022-04-18 Hochstufung Wells Fargo Equal Weight → Overweight
2022-03-08 Herabstufung Stifel Buy → Hold
2022-03-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-04 Bestätigt Barclays Equal Weight
2022-02-04 Bestätigt BofA Securities Neutral
2022-02-04 Bestätigt Cowen Outperform
2022-02-04 Bestätigt Morgan Stanley Overweight
2022-02-04 Bestätigt Needham Buy
2022-02-04 Bestätigt Oppenheimer Outperform
2022-02-04 Bestätigt RBC Capital Mkts Sector Perform
2022-02-04 Bestätigt Robert W. Baird Neutral
2022-02-04 Bestätigt Wedbush Neutral
2022-02-04 Bestätigt Wells Fargo Equal Weight
2022-02-04 Bestätigt Wolfe Research Peer Perform
2022-01-13 Herabstufung Guggenheim Buy → Neutral
2022-01-12 Herabstufung Piper Sandler Overweight → Neutral
2021-12-10 Fortgesetzt Raymond James Mkt Perform
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-09-23 Eingeleitet Needham Buy
2021-06-18 Hochstufung Piper Sandler Neutral → Overweight
2021-06-14 Bestätigt Truist Buy
2021-06-11 Hochstufung Bernstein Mkt Perform → Outperform
2021-06-10 Hochstufung UBS Neutral → Buy
2021-06-08 Hochstufung Atlantic Equities Underweight → Neutral
2021-06-08 Bestätigt Barclays Equal Weight
2021-06-08 Hochstufung Citigroup Sell → Neutral
2021-06-08 Bestätigt H.C. Wainwright Buy
2021-06-08 Bestätigt Jefferies Buy
2021-06-08 Bestätigt Morgan Stanley Overweight
2021-06-08 Bestätigt RBC Capital Mkts Sector Perform
2021-06-08 Hochstufung Robert W. Baird Underperform → Neutral
2021-06-08 Bestätigt Stifel Buy
2021-06-08 Hochstufung William Blair Mkt Perform → Outperform
2021-06-07 Hochstufung BofA Securities Underperform → Neutral
2021-06-07 Hochstufung Cowen Market Perform → Outperform
2021-06-07 Hochstufung Raymond James Underperform → Mkt Perform
2021-02-05 Herabstufung DZ Bank Buy → Hold
2021-01-29 Hochstufung Stifel Hold → Buy
2020-11-10 Hochstufung DZ Bank Hold → Buy
2020-11-09 Herabstufung Atlantic Equities Neutral → Underweight
2020-11-09 Herabstufung BofA Securities Neutral → Underperform
2020-11-09 Herabstufung Cowen Outperform → Market Perform
2020-11-09 Bestätigt H.C. Wainwright Buy
2020-11-04 Hochstufung BofA Securities Underperform → Neutral
2020-11-04 Hochstufung Jefferies Hold → Buy
2020-11-04 Hochstufung Wells Fargo Equal Weight → Overweight
2020-10-28 Eingeleitet UBS Neutral
2020-07-27 Hochstufung Morgan Stanley Underweight → Overweight
2020-06-22 Herabstufung Barclays Overweight → Equal Weight
2020-06-22 Bestätigt RBC Capital Mkts Sector Perform
2020-06-09 Herabstufung Bernstein Outperform → Mkt Perform
2020-04-23 Herabstufung Citigroup Neutral → Sell
2020-04-23 Herabstufung Raymond James Mkt Perform → Underperform
2020-03-31 Eingeleitet Wolfe Research Peer Perform
2020-02-27 Eingeleitet Barclays Overweight
2020-01-27 Hochstufung Canaccord Genuity Hold → Buy
2019-12-13 Hochstufung Credit Suisse Underperform → Neutral
2019-12-02 Herabstufung Robert W. Baird Neutral → Underperform
Alle ansehen

Biogen Inc Aktie (BIIB) Neueste Nachrichten

pulisher
Feb 09, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Bought by Retirement Systems of Alabama - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Biogen FY2024 EPS Estimate Decreased by Cantor Fitzgerald - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

North Growth Management Ltd. Boosts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Entropy Technologies LP Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Biogen (BIIB) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Feb 08, 2025
pulisher
Feb 08, 2025

Biogen Inc. (NASDAQ:BIIB) Stake Boosted by Mirae Asset Global Investments Co. Ltd. - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Greenleaf Trust Has $775,000 Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Win Advisors Inc. Buys New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

Biogen (BIIB) to Release Earnings on Tuesday - MarketBeat

Feb 07, 2025
pulisher
Feb 07, 2025

12 Best Healthcare Stocks to Buy According to Analysts - Insider Monkey

Feb 07, 2025
pulisher
Feb 07, 2025

As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals - BioSpace

Feb 07, 2025
pulisher
Feb 07, 2025

Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance

Feb 07, 2025
pulisher
Feb 06, 2025

IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire

Feb 06, 2025
pulisher
Feb 06, 2025

Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Feb 06, 2025
pulisher
Feb 05, 2025

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Feb 05, 2025
pulisher
Feb 05, 2025

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Cantor Fitzgerald cuts Biogen stock price target to $206 By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Cantor Fitzgerald cuts Biogen stock price target to $206 - Investing.com

Feb 05, 2025
pulisher
Feb 05, 2025

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Feb 05, 2025
pulisher
Feb 05, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Old North State Wealth Management LLC - MarketBeat

Feb 05, 2025
pulisher
Feb 05, 2025

abrdn plc Reduces Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

Judge Explains Biogen Class Cert. Ruling After 1st Circ. Order - Law360

Feb 04, 2025
pulisher
Feb 04, 2025

Global Water Flavouring Drops Market Poised for Substantial Growth, Projected to Reach USD 73.91 Billion by 2035 | Future Market Insights, Inc. - GlobeNewswire Inc.

Feb 04, 2025
pulisher
Feb 04, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Sold by China Universal Asset Management Co. Ltd. - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Forsta AP Fonden - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

FY2025 EPS Estimates for Biogen Lowered by Leerink Partnrs - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

Sumitomo Life Insurance Co. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

Cairn Investment Group Inc. Sells 3,153 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

One week after Netherlands defeat Biogen takes the win in Germany - JUVE Patent

Feb 03, 2025
pulisher
Feb 03, 2025

BRIEF—EC calls for update on regulatory review of lecanemab - The Pharma Letter

Feb 03, 2025
pulisher
Feb 03, 2025

Robeco Institutional Asset Management B.V. Has $62.43 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 03, 2025
pulisher
Feb 02, 2025

Tardive Dyskinesia Treatment Market Report Analysis - openPR

Feb 02, 2025
pulisher
Feb 02, 2025

(BIIB) Investment Analysis and Advice - Stock Traders Daily

Feb 02, 2025
pulisher
Feb 02, 2025

FY2027 EPS Estimates for Biogen Reduced by Leerink Partnrs - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? - MSN

Feb 02, 2025
pulisher
Feb 02, 2025

Smith Group Asset Management LLC Purchases New Shares in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

12 Best S&P 500 Stocks to Invest in According to Analysts - Insider Monkey

Feb 02, 2025
pulisher
Feb 01, 2025

Kirr Marbach & Co. LLC IN Sells 4,578 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

Citigroup Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat

Jan 31, 2025
pulisher
Jan 31, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union - GlobeNewswire

Jan 31, 2025
pulisher
Jan 31, 2025

Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch

Jan 31, 2025
pulisher
Jan 31, 2025

Leqembi review stalls again at European regulator - BioWorld Online

Jan 31, 2025
pulisher
Jan 31, 2025

Biogen Stock Price | BIIB Stock Quote, News, and History - Markets Insider

Jan 31, 2025
pulisher
Jan 31, 2025

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga

Jan 31, 2025
pulisher
Jan 31, 2025

Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters

Jan 31, 2025
pulisher
Jan 31, 2025

Biogen, Eisai Say EU Panel Set to Discuss Additional Safety Data on Lecanemab -January 31, 2025 at 08:10 am EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug - Bloomberg

Jan 31, 2025
pulisher
Jan 31, 2025

Europe to review safety data for Eisai-Biogen Alzheimer’s drug - 1470 & 100.3 WMBD

Jan 31, 2025
pulisher
Jan 31, 2025

Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi - MarketWatch

Jan 31, 2025
pulisher
Jan 31, 2025

Biogen stock in focus as Alzheimer’s drug review delayed (BIIB) - Seeking Alpha

Jan 31, 2025

Finanzdaten der Biogen Inc-Aktie (BIIB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$96.04
price down icon 2.04%
drug_manufacturers_general SNY
$53.35
price up icon 0.91%
drug_manufacturers_general PFE
$25.74
price down icon 0.35%
$293.54
price down icon 1.42%
drug_manufacturers_general NVS
$106.26
price down icon 0.67%
drug_manufacturers_general MRK
$87.28
price down icon 0.87%
Kapitalisierung:     |  Volumen (24h):